SUMMARY The monoclonal antibody Myc l-6E10 was used to determine the cellular distribution of the c-myc oncogene product p62c-rnc in 60 mucinous ovarian tumours. Three patterns of immunostaining were apparent: (i) nuclear staining alone; (ii) staining of the nucleus and basal cytoplasm; and (iii) staining of the entire cell. Of the 21 cases of mucinous cystadenoma, 11 showed nuclear staining alone, and a further case showed additional weak staining of the basal cytoplasm. Nuclear staining alone was not present in any of the 17 borderline mucinous tumours examined. Strong staining of the nucleus and basal cytoplasm was seen in 16 of these borderline cases, six of which also showed focal staining of the apical cytoplasm. All 22 cases of mucinous cystadenocarcinoma showed staining of the cell nucleus and entire cell cytoplasm. Focal staining of the apical cytoplasm in six of 17 borderline mucinous tumours produced a pattern of c-myc immunostaining similar to that of cystadenocarcinoma. Retrospective analysis of the clinical data showed that no significant differences between patients with borderline tumours of these two categories could be defined.
Oncogenes are highly conserved regions of the normal genome. A change in the coding or controlling regions of these genes has been implicated in the pathogenesis of neoplasia. The human c-myc oncogene is a cellular homologue of the avian v-myc gene found in some leukaemogenic retroviruses. The gene has been shown to have an important role in early embryogenesis,' the control of cell growth,2 cellular differentiation34 and in tissue repair processes.5 Expression of the gene is therefore considered to be a major component in the regulatory processes associated with normal cell proliferation and differentiation. This view is reinforced by the demonstration of gene amplification or an increase in the level of gene product p62C`myc in a variety of pathological states in which there is a perturbation of cell proliferation and differentiation, and these include several malignant"8 and premalignant conditions. 9 Ovarian neoplasia is an important cause of Correlation between P62c-mYc and malignancy in ovarian neoplastic disease do occur, often a considerable time after definitive treatment has been performed. '5 Whilst the role of c-myc has been studied in ovarian tumour cell lines'2 and in a single unspecified in vivo ovarian cancer,'3 no attempt has previously been made to examine its role in this important category of ovarian tumour. This present study therefore investigates the expression ofthe gene in such tumours using the monoclonal antibody Mycl-6E10 in an immunohistochemical demonstration of the c-myc oncogene product p62C`UY.
Material and methods
Tumour tissue blocks were obtained from 60 patients with mucinous ovarian tumours presenting between 1979 and 1985. Using standard histological criteria these tumours were classified into benign mucinous cystadenoma (n = 21), malignant mucinous cystadenocarcinoma (n = 22), and borderline mucinous tumours (n = 17). Borderline tumours were characterised by epithelial stratification and atypia, the presence of epithelial tufting, and evidence of mitotic activity in the absence of stromal invasion.
Case notes from 58 patients were available for review. The mean age at presentation ofthose patients with benign, borderline, and malignant tumours was 45.7, 47 0, and 61-7 years, respectively. Analysis of these data using the unpaired t test showed a significant difference between those with malignant disease and those with benign or borderline lesions (p < 0-01). Most Sections were cut at 4 jm and placed on glass microscope slides and oven-dried at 50°C overnight. Sections were dewaxed and rehydrated using xylene and alcohols, and endogenous proxidase was blocked by a 10 minute incubation in 0-5% hydrogen peroxide in methanol. The sections were washed briefly and incubated for two hours in Myc 1-6E10, diluted 1/10 000 in Tris-buffered saline with 1% bovine serum albumin and 0-25% Triton X-100 (pH 7 3). After further washing biotinylated sheep anti-mouse immunoglobulin was applied to the sections at a dilution of 1/100 and incubated for 60 minutes. After additional washes an incubation in Vectorstain ABC reagent (Vector Labs, England) was performed for one hour, followed by a final incubation in diaminobenzidine (100 mg in 200 ml 0 5% hydrogen peroxide solution) for 10 minutes. The sections were washed in tap water and counterstained in Harris's haematoxylin for 60 seconds.
All washes were performed using Tris-buffered saline containing 1% bovine serum albumin, and incubations were at room temperature.
Specificity of Mycl-6E10 has previously been investigated and its immunoreactivity found to be annulled by addition of the peptide used as immunogen in the production of the antibody. ' (fig 2) , six of which also showed focal staining of the apical cytoplasm (fig 3) . A further case failed to stain with the antibody. All 22 cases of mucinous cystadenocarcinoma showed weak staining of the nucleus and moderate to strong staining of basal and apical cytoplasm (fig 4) . Staining intensity was noted to be generally reduced in poorly differentiated tumours.
All tumour categories showed focal expression of the c-myc gene in stromal fibroblasts, inflammatory cells (particularly lymphocytes and plasma cells), and vascular endothelial cells.
Focal staining of the apical cell cytoplasm in six of 17 borderline mucinous tumours produced a pattern of c-myc immunostaining similar to that of cystadenocarcinoma, although the intensity of apical staining in the borderline tumours tended to be less. These cases were separately analysed with respect to patient's age, mode of presentation, and subsequent progress (table 2) . Using these variables no difference between the two subgroups of borderline tumour could be defined.
Discussion
The role of cellular oncogenes in the development of ovarian neoplasia has received relatively scant attention. We have shown both expression of the c-myc gene in mucinous ovarian neoplasms and a correlation between the cellular distribution of the gene product p62c"mYc and the tumour category. amplification is present, although this is not invariable, and indeed c-myc deregulation within neoplastic cells may also occur by gene mutation, gene rearrangement, or promotor insertion. '9 Amplification of the c-myc oncogene has been shown in ovarian cancer,'3 where DNA extracted from tumour cells showed gene amplification in three of 11 cases. DNA from tumour metastases and circulating blood leucocytes showed similar amplification in two of 11 cases. Amplification of the c-myc gene has also recently been shown in the ovarian tumour cell lines OS-4 and OvCa-1. 2 Where specifically examined, a close correlation has been shown between c-myc mRNA copy number and p62c-mYc abundance as determined by immunocytochemistry. '8 This correlation fully supports the use of Myc 1-6E10 in the assessment of c-myc gene activity in clinical material.
In the present study an assessment of p62C-mYc abundance based on the cellular distribution of the gene product or staining intensity would be unjustified; within any one tumour category, however, such an assessment might be valid. Staining intensity seemed to vary most in the malignant mucinous tumours, where the least differentiated neoplasms stained most weakly. Similar observations have been made in colonic'820 and testicular cancer2' and would be consistent with a role for the gene product in cellular differentiation. The clinical importance of these observations is supported by the reported correlation between low concentrations of p62cmYc and poor disease outcome. 22 The overall distribution of p62c-mYc shown in this study is similar to that reported in glandular neoplasms elsewhere in the body. Malignant neoplasms show both an increased volume of distribution of the gene product and an overall change in the cellular compartments containing the product, with a much greater emphasis on the cell cytoplasm. '8 22 This may in part be related to mucin depletion in malignant tumours with a consequent loss ofmucin vacuoles and thus a potentially greater volume for distribution of the gene product in the malignant cell. The cellular distribution of the gene product may also represent a genuine change in the biology of the malignant cell.
The c-myc gene product is normally associated with the cell nucleus, a feature related to the known DNA binding of the protein product. 23 Evidence from the present study shows that this nuclear association of Polacarz, Hey, Stephenson, Hill p62C-mYc is strongly maintained in benign mucinous tumours of the ovary but it becomes more tenuous in borderline tumours, until ultimately in malignant tumours most gene product appears in the cytoplasm of the cell. Predominantly cytoplasmic staining has also been reported in colonic adenomas,20 while colonic carcinoma" and untreated coeliac disease24 show both a nuclear and cytoplasmic distribution of the gene product. The cytoplasmic distribution of p62C-mYc has provoked concern in previous studies, with a suggestion that this distribution may be artefactual. This concern has been countered, however, by the observation in familial polyposis that the staining pattern of normal colonic epithelium is quite different from that of the epithelium of adjacent adenomatous polyps in the same immunocytochemical preparation. 25 In normal mucosa nuclear staining is seen, but the adenomatous polyps show cytoplasmic staining. Identical patterns of immunostaining were also seen using the alternative antibodies Myc-CT14 and pan-myc. These antibodies recognise different epitopes on the c-myc gene product from that recognised by Myc I-6E10. It seems likely, therefore, that the differing patterns of gene product distribution do indeed reflect a modification of the biology of the neoplastic cell.
This study has shown that borderline tumours ofthe ovary display a pattern of immunostaining which in most cases seems to be distinct from either benign or malignant tumour categories. Six of the 17 cases of borderline tumour, however, showed a pattern of staining focally identical with that seen in malignant tumours. Subsequent analysis of these cases has not shown any difference in biological behaviour of these tumours when compared with the remaining borderline cases. In view of the occasional late recurrence of borderline mucinous tumours these cases are the subject of a further prospective study. As the pattern ofimmunostaining alone might suggest a more aggressive clinical course than was in fact the case we conclude that standard histological criteria are more accurate indicators of tumour behaviour than is an assessment of c-myc expression. Recent work on the ras gene in advanced ovarian cancer has shown a similar poor correlation, not only between gene expression and clinical outcome, but also between expression and histological grade and ploidy.'426
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